Evidence map›Paper›PMID 31944498›Full record

ArticlePediatric transplantation2020

Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report.

Meghan L Good, Parisa Malekzadeh, Isaac R Kriley, Nirali N Shah, David E Kleiner, Katherine Calvo, Jonathan M Hernandez, Jeremy L Davis

Open access · greenAbstract readCase Reports
In one paragraph

Article in Pediatric transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Meghan L GoodSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-3988-1365
Parisa MalekzadehSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Isaac R KrileySurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nirali N ShahPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-8474-9080
David E KleinerLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Katherine CalvoLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jonathan M HernandezSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jeremy L DavisSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
National Institutes of Health · US

Funding

Postmortem PathologyZICBC010685 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLEINER, DAVID ERWIN · 2009 to 2025
$14.3M
Evaluating outcomes for patients with primary-metastatic gastrointestinal cancerZIABC011861 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HERNANDEZ, JONATHAN · 2019 to 2025
$166k
Intramural NIH HHS ZIA BC011861
6 · The paper itself

Abstract

Secondary malignancies are a significant cause of non-relapse mortality in patients who undergo allogeneic HCT. However, secondary liver cancer is rare, and ICC following HCT has never been reported in the literature. Secondary solid cancers typically have a long latency period, and cholangiocarcinoma is classically a malignancy occurring in older individuals. Here, we report the first case of secondary ICC, which presented just 3 years after HCT in a young adult with a history of childhood ALL. A 26-year-old male with history of precursor B-cell ALL presented with asymptomatic elevated liver function tests 3 years after HCT. Laboratories were indicative of biliary obstruction. ERCP showed focal biliary stricturing of the common and left hepatic ducts. MRCP revealed left intrahepatic duct dilatation, suggestive of intrahepatic obstructing mass. Additional workup lead to a clinical diagnosis of ICC. The patient underwent left hepatectomy with extrahepatic bile duct resection and portal lymphadenectomy. Surgical pathology was consistent with moderately differentiated cholangiocarcinoma. Our case illustrates a rare SMN following HCT for ALL. It is the first case report of ICC occurring as a secondary cancer in this patient population. Although cholangiocarcinoma is characteristically diagnosed in the older population, it must remain on the differential for biliary obstruction in post-HCT patients.

Indexed as

Hepatic Duct, CommonAdultBile Duct NeoplasmsCholangiocarcinomaHematopoietic Stem Cell TransplantationHumansMalePrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation, Homologousacute lymphoblastic leukemiabone marrow transplantcase reportcholangiocarcinomahematopoietic stem cell transplantIntrahepatic cholangiocarcinomasecondary malignancy

Identifiers

PMID31944498
PMCPMC8453586
OpenAlexW3000703533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.